Amgen stock extends 2026 rally as Q2 earnings beat and guidance lifted
Published on 08/19/2026 at 09:22 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Amgen Inc. (ISIN US0311621009) stock is trading at $425.76 on Nasdaq as of August 19, 2026, supported by double-digit year-over-year revenue growth and raised full-year 2026 guidance after a solid second-quarter earnings beat.
Recent market data as of August 19, 2026 show the shares holding close to their intraday high following stronger-than-expected earnings that pushed Amgen’s price above $425 and kept trading volume near its typical daily level. Per a detailed quote overview href='https://robinhood.com/us/en/stocks/AMGN/' title='Robinhood AMGN stock quote' style='text-decoration:underline dotted;'>market data, the stock has been changing hands between a low of $420.66 and a high of $428.00 on the day.
Q2 2026 earnings beat with high-single-digit growth
In its second quarter of 2026, Amgen reported revenue of $10,054 million, representing a 9.5 percent increase compared with the prior-year period revenue of $9,183 million, highlighting continued expansion across its portfolio.
The company also delivered net income of $2,375 million in Q2 2026, translating into strong profitability alongside the top-line growth. Earnings per share for the quarter reached $6.29, beating the consensus estimate of $5.62 by $0.67 and underscoring management’s ability to execute.
Profitability metrics from the same earnings release show Amgen generating a return on equity of 124.14 percent and a net margin of 22.95 percent in Q2 2026, signaling efficient use of capital and healthy margins in the biopharmaceutical business.
Full-year 2026 guidance and valuation context
Looking ahead to the full year, Amgen has issued total revenue guidance for 2026 in the range of $38.20 billion to $39.40 billion, indicating confidence in delivering continued mid- to high-single-digit growth versus its current annualized run rate.
For earnings, management has set full-year 2026 GAAP EPS guidance between $22.30 and $23.50, a range that sits above analysts’ current forecast of 22.78 earnings per share, suggesting room for upside if operating trends remain favorable.
On August 19, 2026, Amgen’s market capitalization stands at $229.94 billion based on the $425.76 share price, implying a price-to-earnings ratio of 26.05 and a dividend yield of 2.34 percent that together frame the stock’s valuation and income profile in the large-cap biotech universe.
Analyst sentiment and price-target dynamics
Analyst sentiment on Amgen in August 2026 is mixed but improving, with a broad consensus rating characterized as Hold and an average price target around the low-to-mid $370s, suggesting that the recent share price strength has run ahead of many existing models.
At the same time, fresh research has highlighted the strength of Amgen’s core portfolio and raised individual price targets to the mid-$420s range as of August 18, 2026, reflecting growing conviction in the sustainability of the current earnings trajectory.
Year to date in 2026, Amgen shares are up 30 percent, while the 12-month performance shows a gain of nearly 48 percent, underscoring how the combination of earnings beats, guidance raises and portfolio momentum has translated directly into shareholder returns.
Dividend profile and cash returns
Beyond earnings, Amgen continues to return cash to shareholders through a regular dividend. For the second quarter of 2026, the company declared a cash dividend of $2.52 per share, with a record date of May 15, 2026 and payment scheduled for June 5, 2026.
At the current share price of $425.76 as of August 19, 2026, the annualized dividend stream implied by recent payouts supports a dividend yield of 2.34 percent, offering investors a blend of income and growth in addition to exposure to innovative therapeutics.
Historically, Amgen has supplemented dividends with share repurchases, and the strong net margin of 22.95 percent reported in Q2 2026 indicates sufficient earnings capacity to maintain a shareholder-friendly capital allocation framework if market conditions remain stable.
Flagship products underpinning revenue growth
Amgen’s revenue base in 2026 is underpinned by a diversified portfolio of biologic therapies and newer products that target oncology, inflammatory conditions and cardiovascular risk, providing multiple drivers for the mid- to high-single-digit revenue growth seen in Q2 2026.
The company’s pipeline strategy remains focused on advancing first-in-class and best-in-class molecules, with recent approvals and label expansions contributing incrementally to the $10,054 million revenue figure reported in the second quarter of 2026.
For investors, the resilience of these flagship therapies and the breadth of the pipeline are key qualitative supports behind the quantitative guidance ranges of $38.20 billion to $39.40 billion in full-year 2026 revenue and $22.30 to $23.50 in GAAP EPS.
Shares trade above recent targets
From a market-technical perspective, Amgen stock’s $425.76 level as of August 19, 2026 places the shares slightly below the intraday high of $428.00 but solidly above the session low of $420.66, indicating a tight trading range around new highs.
The current price also sits above many published average price targets in the low-to-mid $370s, highlighting that the market is already pricing in a portion of the earnings and guidance strength while new research at the mid-$420s range suggests further potential alignment between targets and the latest price action.
With a current trading volume of 2.59 million shares versus an average daily volume of 2.65 million as of August 19, 2026, interest in Amgen remains robust but not overheated, which may help stabilize the stock as investors digest the recent Q2 2026 figures and full-year outlook.
Amgen’s biopharmaceutical platform
Amgen’s core business model in 2026 centers on discovering, developing and manufacturing human therapeutics, leveraging expertise in biologics, antibodies and biosimilars to address serious diseases with high unmet medical need.
The company’s integrated platform allows it to move drug candidates from research into clinical development and eventual commercialization, supporting a pipeline of treatments that can sustain the multi-billion-dollar revenue base reflected in the $10,054 million Q2 2026 sales figure.
As regulatory and competitive dynamics evolve, Amgen’s scale and experience in large-molecule manufacturing, coupled with its established global distribution network, position it to defend margins such as the 22.95 percent net margin reported in Q2 2026 while continuing to invest in new therapies.
Stock level and investor takeaway
As of August 19, 2026, Amgen stock trades on Nasdaq under the ticker AMGN at $425.76, within a daily range of $420.66 to $428.00, with a price-to-earnings ratio of 26.05 and a dividend yield of 2.34 percent that frame the shares’ current valuation.
For US retail investors, the key numbers to watch now are the revenue guidance band of $38.20 billion to $39.40 billion and the GAAP EPS range of $22.30 to $23.50 for 2026, alongside the recent 9.5 percent year-over-year revenue growth to $10,054 million and the Q2 2026 EPS beat to $6.29, which collectively underpin the stock’s strong performance so far this year.
Fact box
Company: Amgen Inc.
ISIN: US0311621009
Ticker: AMGN
Exchange: Nasdaq
Price (as of August 19, 2026, 4:01 a.m. ET): $425.76 USD
Market cap: $229.94 billion (as of August 19, 2026)
Sector / Industry: Health care / Biotechnology
Index membership: S&P 500
